

REMARKS:

In response to the Restriction Requirement dated April 9, 2008, the response term to which has been extended by two months, the applicants hereby elect Group III, namely claim 30 drawn to a method of preventing or treating an at least partially therapy-resistant hyperproliferative disorder by administering an inhibitor of a receptor tyrosine ligand to a subject in need thereof.

This election is with traverse, as the Examiner has not established that the claims lack unity under the appropriate PCT Rules. All of the claims in the application are directed to an inhibitor of a receptor tyrosine kinase ligand or use thereof, and this inhibitor is the technical feature linking all of the claims as a single general inventive concept. Since the Examiner's rationale for requiring restriction does not deal with this special technical feature, it is believed that the Restriction Requirement should be reconsidered and withdrawn.

Withdrawal of the Restriction Requirement and early and favorable action on the merits is awaited.

The use claims have been rewritten as method of treatment claims, as kindly suggested by the Examiner.

Respectfully submitted,

By


Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb